HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Pier Luigi Filosso Enrico Ruffini Giovanni Donati Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Filosso, P. L. Articles by Rena, O. Search for Related Content PubMed PubMed Citation Articles by Filosso, P. L. Articles by Rena, O. Related Collections Lung - cancer Trachea and bronchi

Eur J Cardiothorac Surg 2002;21:913-917
© 2002 Elsevier Science NL

Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide

Department of Thoracic Surgery, San Giovanni Battista Hospital, University of Torino, Via Genova 3, 10126 Turin, Italy

Received 14 September 2001; received in revised form 8 January 2002; accepted 16 January 2002.

* Corresponding author. Tel.: +39-11-633-6635; fax: +39-11-696-0170
e-mail: pierluigifilosso{at}tiscalinet.it

Objective: To demonstrate that liver metastases by radically resected atypical carcinoids of the lung can be effectively treated by new somatostatin analogs. Methods: Between January 1977 and December 1999, 126 patients affected by bronchial carcinoids were submitted to a radical resection of the lung. Seven of them (5.5%) presented liver metastases 27, 22, 14, 18, 16, 12 and 9 months after surgery: carcinoid syndrome (CS) was ever present. ¹¹¹In–DTPA–pentetreotide scintigraphy (Octreoscan) and ultrasound guided biopsy were performed in all cases, and the presence of somatostatin receptors sst₂ was demonstrated by polymerase chain reaction (PCR) method. Results: Five patients refused the proposed chemotherapy, and liver alcoholization was not feasible. Octreotide was administered at the dose of 1500 µg/daily subcutaneously. CS was controlled and also high urinary 5-hydroxyindoleacetic acid values returned to normal after a median of 7 days (range 4–10 days) of medical treatment. No important side effects were registered, and a good quality of life was observed. The patients are alive and well at 51, 36, 24, 24, 23, 19, and 16 months after the diagnosis of the metastases, respectively. In two cases ultrasounds revealed the reduction and in one case the complete resolution of the liver lesion. Conclusions: Octreotide is effective in controlling symptoms of CS of patients with liver metastases of resected atypical bronchial carcinoid. The efficacy of the drug is due to the presence of sst₂ somatostatin receptors in the pathologic tissue, as demonstrated by PCR method. The positivity to Octreoscan depends on the presence of the same receptors. Octreoscan may be used in the follow-up of these neuroendocrine neoplasms of the lung. A positivity to Octreoscan is predictive for an effective therapy with octreotide.

Key Words: Lung • Neuroendocrine tumors • Liver metastases • Octreotide • Scintigraphy • Survival

This article has been cited by other articles:

				A. S. Ho, J. Picus, M. D. Darcy, B. Tan, J. E. Gould, T. K. Pilgram, and D. B. Brown Long-Term Outcome After Chemoembolization and Embolization of Hepatic Metastatic Lesions from Neuroendocrine Tumors Am. J. Roentgenol., May 1, 2007; 188(5): 1201 - 1207. [Abstract] [Full Text] [PDF]

				R. J. Battafarano, F. G. Fernandez, J. Ritter, B. F. Meyers, T. J. Guthrie, J. D. Cooper, and G. A. Patterson Large cell neuroendocrine carcinoma: An aggressive form of non-small cell lung cancer J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 166 - 172. [Abstract] [Full Text] [PDF]

				P. L. Filosso, E. Ruffini, A. Oliaro, O. Rena, C. Casadio, M. Mancuso, D. Turello, R. C. Cristofori, and G. Maggi Large-cell neuroendocrine carcinoma of the lung: A clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide J. Thorac. Cardiovasc. Surg., April 1, 2005; 129(4): 819 - 824. [Abstract] [Full Text] [PDF]

				G. A. Kaltsas, G. M. Besser, and A. B. Grossman The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors Endocr. Rev., June 1, 2004; 25(3): 458 - 511. [Abstract] [Full Text] [PDF]

				P. L. Filosso, A. Arslanian, N. Palestini, A. Farnetti, M. Papotti, M. Bongiovanni, R. Giobbe, and E. Ruffini Thyroid metastasis after resection of atypical bronchial carcinoid J. Thorac. Cardiovasc. Surg., June 1, 2004; 127(6): 1840 - 1843. [Full Text] [PDF]

				P. L. Filosso, G. M. Actis Dato, E. Ruffini, S. Bretti, F. Ozzello, and M. Mancuso Multidisciplinary treatment of advanced thymic neuroendocrine carcinoma (carcinoid): Report of a successful case and review of the literature J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1215 - 1219. [Full Text] [PDF]

				R. Hage, A. B. de la Riviere, and J.M.M. van den Bosch Reply to Filosso Eur. J. Cardiothorac. Surg., October 1, 2003; 24(4): 673 - 673. [Full Text] [PDF]

				P. L. Filosso Possible Tx N2 M0 atypical bronchial carcinoid associated with Cushing syndrome J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 1224 - 1225. [Full Text] [PDF]

				P. L. Filosso and E. Ruffini Synchronous bilateral typical carcinoid of the lung Eur. J. Cardiothorac. Surg., July 1, 2003; 24(1): 174 - 174. [Full Text] [PDF]

				P. L. Filosso, G. Donati, O. Rena, and A. Oliaro Acromegaly as Manifestation of a Bronchial Carcinoid Tumour Asian Cardiovasc Thorac Ann, June 1, 2003; 11(2): 189 - 189. [Full Text] [PDF]

				P. L. Filosso Large cell neuroendocrine carcinoma of the lung: What we have to do J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 1182 - 1183. [Full Text] [PDF]

				P. L. Filosso, O. Rena, E. Ruffini, A. Oliaro, and L. H. Harrison Intraoperative OctreoScan and Management of Bronchial Carcinoid Chest, October 1, 2002; 122(4): 1493 - 1494. [Full Text] [PDF]